Gilead Allowed To Submit New Evidence In Patent Case After Claiming Merck’s Lawyer Lied
The California-based company alleges the lawyer misused what he learned on a conference call to change pending applications.
The Wall Street Journal:
Judge Allows More Evidence In Patent Dispute After Gilead Says Merck Attorney Lied
A federal judge has allowed Gilead Sciences Inc. to submit additional evidence in a drug-patent dispute with Merck & Co., after Gilead claimed a former Merck patent attorney lied under oath in the case. In March, a federal jury in San Jose, Calif., ordered Gilead to pay Merck $200 million after finding that two U.S. patents held by Merck and its partner, Ionis Pharmaceuticals Inc., were valid and infringed by Gilead’s multibillion-dollar hepatitis C drugs, Sovaldi and Harvoni. The trial arose from Gilead’s 2013 lawsuit seeking a judgment that the Merck patents were invalid. (Loftus, 5/2)